{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, et al.', 'gamma-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat', 'Commun. 2015; 6:7333.', 'Macsai M, Nariani A, Gan H, Lassman A, Merrell R, Gomez E, et al. Corneal Toxicity of', 'ABT-414 in Glioblastoma (GBM): Clinical Manifestations, Ophthalmological Findings', 'and Management. Investigative Ophthalmology & Visual Science. 2016 Sep', '26;57(12):269-269.', 'Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, et al. Development', 'of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol.', '2001;119(7):1050-8.', 'Moskowitz CH, Fanale MA, Shah BD, Advani RH, Chen R, Kim S, Kostic A, et al. A', 'phase 1 study of denintuzumab mafodotin (SGN-CD19A) in Relapsed/Refractory B-', \"lineage non-hodgkin's lymphoma. Blood. 2015; 126:182.\", 'NCCN (2016). Multiple Myeloma. Version 3.2017 - November 28, 2016. NCCN', 'Clinical Practice Guidelines in Oncology (NCCN Guidelines), 58.', 'NCI (2010) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.', 'In: Health NIo, editor. https://evs.nci.nih.gov/ftpl/CTCAE/CTCAE_4.03_2010-06', '14_QuickReference_5x7.pdf U.S. Department of Health and Human Services.', 'Neuenschwander B, Branson M and Gsponer T. Critical aspects of the Bayesian approach', 'to Phase I cancer trials. Statistics in Medicine 2008; 27:2420-39.', 'Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al.', 'Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for', 'growth and survival. Blood. 2004;103(2):689-94', 'NYHA. The Criteria Committee of the New York Heart Association. Nomenclature and', 'Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Ed. Boston, Mass:', 'Little, Brown & Co. 1994:253-256.', 'Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, et al. Validation of', 'the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related', 'macular degeneration. Invest Ophthalmol Vis Sci. 2011;52(6):3354-9.', 'Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Boyd MR, Hamel E, et al.', 'Antineoplastic agents 365. Dolastatin 10 SAR probes. Anticancer Drug Des.', '1998;13(4):243-77', 'Proskorovsky I., P. Lewis, C. D. Williams, K. Jordan, C. Kyriakou, J. Ishak, F. E. Davies.', 'Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple', 'myeloma. Health Qual Life Outcomes. 2014 Mar 11; 12:35.', '102']['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al.', 'International Myeloma Working Group updated criteria for the diagnosis of multiple', 'myeloma. The Lancet Oncology. 2014;15: e538-e548.', 'Rajkumar SV, Richardson P, San Miguel JF. Guidelines for the determination of the', 'number of prior lines of therapy in multiple myeloma. Blood. 2015; 126:921-922.', 'Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and', 'management. Am J Hematol. 2011 Jan;86(1):57-65. doi: 10.1002/ajh.21913', 'Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma.', 'Am Soc Clin Oncol Educ Book. 2016;35: e418-23.', 'Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, et al.', 'Efficacy and safety results of ABT-414 in combination with radiation and temozolomide', 'in newly diagnosed glioblastoma. Neuro-oncology. 2016; 19:965-975.', 'Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al.', 'Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and', 'refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123:1826-1832;', 'doi: https://doi.org/10.1182/blood-2013-11-538835', 'Sanchez E, Li M, Kitto A, LiJ, Wang CS, Kirk DT, et al. Serum B-cell maturation', 'antigen is elevated in multiple myeloma and correlates with disease status and survival.', 'Br J Haematol. 2012;158(6):727-38', 'Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and', 'validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615-21.', 'Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of', 'single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory', 'multiple myeloma. Blood. 2012;120(14):2817-25.', 'Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-', '30.', 'Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma.', 'Immunotherapy. 2015;7(11):1187-99', 'Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, et al. Role of B-cell-activating', 'factor in adhesion and growth of human multiple myeloma cells in the bone marrow', 'microenvironment. Cancer Res. 2006;66(13):6675-82.', 'Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, et al.', 'Phase I dose-escalation study of SGN-75 in patients with CD70-positive', 'relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.', 'Investigational new drugs. 2014 Dec 1;32(6):1246-57', '103']\n\n###\n\n", "completion": "END"}